Month: March 2022

March 31, 2022

Innovations designed to seamlessly work together, strengthen clinical confidence, build efficiency throughout the care pathway, and improve cardiac care experiences

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced new additions to its innovative integrated portfolio of cardiology solutions at the American College of Cardiology’s Annual Scientific Session & Expo (ACC 2022). Philips’ cardiology portfolio offers solutions for coronary artery disease, structural heart disease, arrhythmia and heart failure. It integrates diagnostic and interventional imaging, treatment devices, and cardiac patient monitoring solutions at each point in the patient journey with the aim to improve clinical outcomes, patient and staff experiences, and care pathway effectiveness.  

Cardiovascular disease continues to be the number one healthcare challenge globally and is one of the leading causes of death worldwide [1]. The costs associated with cardiovascular diseases are rising significantly, with an expected growth in cost of 101% by 2035 [2]. Worldwide, clinicians need to balance the delivery of high-quality care for a growing volume of complex patients with constantly improving departmental efficiency.

Adding to the strength and depth of its cardiology portfolio, at ACC.22 Philips is launching two major innovations. Philips Ultrasound Workspace, an industry leading vendor-neutral echocardiography image analysis and reporting solution that can be accessed via the web, allows clinicians to create seamless diagnostic workflows from the ultrasound exam room to the reporting room and beyond. Philips also announced the global availability of a new Ambient Experience solution connecting to Philips Image Guided Therapy System – Azurion, which aims to reduce patient anxiety during interventional procedures. Ambient Experience with FlexVision display offers patients a calming multi-sensory experience while staff prepare them for their procedure.

Philips Ultrasound Workspace: Next generation echocardiography solution
By offering cardiologists a consistent set of AI-driven automated image analysis and quantification tools for use at any point in the care pathway, together with the ability to perform longitudinal patient studies, Philips Ultrasound Workspace helps to improve productivity and consistency while also enhancing diagnostic quality. Irrespective of location [3], with Ultrasound Workspace, the same user interface and AI-enabled image analysis and quantification tools are now accessible to help speed up quantitative measurements such as left ventricular ejection fraction, increase diagnostic confidence, and improve inter-observer and intra-observer variability.

Introducing the Philips Ambient Experience to interventional rooms
Debuting at ACC.22 is Ambient Experience with FlexVision display. It offers patients undergoing an interventional procedure a calming multi-sensory experience while staff prepare them for their procedure, prior to the display being used for the actual intervention. It also allows patients and interventional team members to adapt the room’s ambient lighting and sound to add to the overall feeling of calm, especially during the patient entry and preparation phases of procedures. Aimed at reducing patient anxiety during interventional procedures, Ambient Experience, leveraging the Azurion’s FlexVision display, has the potential to improve the patient and staff experience, positively impact outcomes, and enhance workflows and productivity.

At ACC, Philips will also spotlight the latest cardiovascular features to Enterprise Performance Analytics – Performance Bridge – giving cardiovascular service line managers access to near real-time data on departmental performance through easy-to-use interactive vendor-neutral dashboards.

With these newest enhancements, users now have access to critical metrics to support operational performance monitoring in a minimally invasive procedural setting such as the interventional suite, providing data on procedure volumes, room utilization, procedure duration and lab turnaround time. Users can also access key metrics designed to support operational performance monitoring in a non-invasive procedural setting such as cardiac imaging suites, most notably echocardiography, with access to data on procedure volumes, modality/machine utilization, study type counts and report turnaround time.

This newest release further demonstrates Philips’ commitment working closely together with healthcare providers to bring together the right combination of services and tools to measure and monitor key areas to help drive continuous improvement, optimized operations, enhanced workflow efficiencies and improved patient outcomes.

Also highlighted at ACC.22 is Philips Image-Guided Therapy System – Azurion, the company’s advanced image-guided therapy platform that supports providers in performing procedures easily and confidently with a unique user experience.

Philips is also showcasing its complete portfolio of ambulatory cardiac diagnostic and monitoring services, as well as stroke care solutions, that provide industry-leading data analysis and management to help make care delivery more comprehensive, accurate and efficient.

New late-breaking clinical session on CIED patient care
On Sunday, April 3 at 13:15-13:25 ET in Main Tent | Hall D, Sean Pokorney, M.D., Assistant Professor of Medicine at Duke University School of Medicine (USA) and member of the Duke Clinical Research Institute, will present on low rates of guideline-directed care associated with higher mortality in patients with infection of pacemakers and implantable cardioverter defibrillators. Philips supports physicians with Lead Management solutions through a broad portfolio of tools designed for safety and predictability, including both laser and mechanical lead extraction devices.

To connect with experts and learn more about the Philips cardiology solutions that strengthen clinical confidence and build efficiency throughout the care pathway stop by Philips booth #1121. For a full calendar of events, as well as general information about Philips’ presence at the show, visit www.philips.com/ACC. Visit the Philips Industry Hub to experience innovative cardiac solutions and follow the #ACC2022 conversation on @PhilipsLiveFrom throughout the event.

[1] European Cardiovascular Disease Statistics 2017.
[2] RTI International for the American Heart Association. Projections of Cardiovascular Disease Prevalence and Costs: 2015–2035.
[3] Remote access requires a secure VPN connection.

For further information, please contact:

Joost Maltha
Philips Global Press Office
Tel: +31 6 10 55 8116
Email: joost.maltha@philips.com

Fabienne van der Feer
Philips Image Guided Therapy
Tel: + 31 622 698 001
E-mail: fabienne.van.der.feer@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Philips Ambient Experience and FlexVision display
• Philips Ultrasound Workspace

• Following earlier harbor wet-testing, the Allseas-designed pilot nodule collector vehicle was deployed from the Hidden Gem and lowered to the seafloor in open sea conditions
• A range of critical drive functions were successfully tested, confirming the collector’s capability to manoeuvre forwards and backwards at various speeds and in different directions, as well as to lower and raise the nodule collector heads
• Allseas engineers successfully tested dynamic positioning systems aboard the Hidden Gem confirming the vessel’s ability to adjust speed and heading as the collector drives across the seafloor.
• Upcoming trials in TMC’s NORI-D contract area are expected to include deployment of a four-kilometer-long riser, an umbilical that provides power and control during seafloor operations, and a 500-meter-long flexible jumper hose to connect to the collector vehicle

NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) — TMC the metals company Inc. (Nasdaq: TMC) (“TMC” or the “Company”), an explorer of the world’s largest estimated undeveloped source of critical battery metals, today announced the successful completion of its North Sea drive test program for the robotic polymetallic nodule collector vehicle designed by the Company’s strategic partner and shareholder, Allseas Group S.A. (“Allseas”).

During the drive test program performed in the Dutch Sector of the North Sea, the Allseas-designed collector vehicle underwent extensive testing of critical mobility and all systems were shown to be functional. Covering a distance of 4,533 meters, Allseas engineers put the collector vehicle through its paces, driving it forwards and backwards at various speeds, and in different directions. In addition, tests were undertaken to raise and lower the vehicle’s adjustable collector heads – another critical function.

“This North Sea drive test is a key milestone that not only shows that our collector can be remotely operated in open seas but that it can do so in parallel motion with the Hidden Gem’s dynamic positioning system,” said Gerard Barron, CEO & Chairman of The Metals Company. “The tests show that the collector can be controlled with a very high level of accuracy that will enable us to build and execute detailed mine plans that respect the bathymetry, sediment characteristics and ecology of the deep seafloor. These trials are proving what we always knew about Allseas, that they take on every engineering task with an unsurpassed attention to detail and this is why they have the highest level of success in the offshore industry.”

The accurate positioning and coordinated movement of the collector vehicle and Hidden Gem will be vital for planned future offshore operations and engineers successfully completed a variety of tests of the vessel’s dynamic positioning system, confirming its ability to adjust speed and heading as the collector drives across the seafloor.

Earlier this month, TMC and Allseas announced the successful wet-testing of the polymetallic nodule collector vehicle and, with this latest round of system tests now complete, Allseas engineers will begin preparations for full pilot nodule collection trials over an 8 km2 section of the NORI-D contract area in the Clarion Clipperton Zone of the Pacific Ocean later this year. These trials are an integral part of the International Seabed Authority’s regulatory and permitting process and the environmental impact data collected both during and after this nodule collection test work will form the basis of the application for an exploitation contract by TMC’s wholly-owned subsidiary, Nauru Ocean Resources Inc. (NORI).

Since 2019, Allseas and TMC have been working together to develop a pilot system to responsibly collect unattached polymetallic nodules from the seafloor and lift them to the surface for transportation to shore. Nodules contain high grades of nickel, manganese, copper and cobalt — key metals required for building electric vehicle batteries and renewable energy technologies.

Development of technologies to collect polymetallic nodules first began in the 1970s when oil, gas and mining majors including Shell, Rio Tinto (Kennecott) and Sumitomo successfully conducted pilot test work in the CCZ, recovering over ten thousand tons of nodules. In the decades since, the ISA was established to develop the regulatory framework to govern mineral extraction in the high seas while technology development efforts have largely focused on scaling proven nodule collection technologies and optimizing for minimal seafloor disturbance and environmental impact.

About The Metals Company

TMC the metals company Inc. (The Metals Company) is an explorer of lower-impact battery metals from seafloor polymetallic nodules, on a dual mission: (1) supply metals for the clean energy transition with the least possible negative environmental and social impact and (2) accelerate the transition to a circular metal economy. The company through its subsidiaries holds exploration rights to three polymetallic nodule contract areas in the Clarion Clipperton Zone of the Pacific Ocean regulated by the International Seabed Authority and sponsored by the governments of Nauru, Kiribati and the Kingdom of Tonga. More information is available at www.metals.co.

About Allseas

Allseas is a world-leading contractor in the offshore energy market, with dynamism, rapid progress and pioneering spirit at its core. Allseas specialise in offshore pipeline installation, heavy lift and subsea construction. The company employs over 4000 people worldwide and operates a versatile fleet of specialised heavy-lift, pipelay and support vessels, designed and developed in-house.

More information about Allseas is available at www.allseas.com

More Info

Media | media@metals.co
Investors | investors@metals.co

Forward Looking Statements

Certain statements made in this press release are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters, including related to upcoming trials in TMC’s NORI-D contract area and future offshore operations. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside TMC’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: Allseas ability to conduct a full pilot nodule collection trial in the Clarion Clipperton Zone; TMC’s ability to enter into definitive agreement(s) with Allseas with respect to the proposed strategic alliance to develop and operate a commercial collection system on terms and conditionals substantially similar to those set forth in the non-binding terms sheet; the successful completion of the pilot collection tests; TMC’s ability to obtain exploitation contracts for its areas in the CCZ; regulatory uncertainties and the impact of government regulation and political instability on TMC’s resource activities; changes to any of the laws, rules, regulations or policies to which TMC is subject; the impact of extensive and costly environmental requirements on TMC’s operations; environmental liabilities; the impact of polymetallic nodule collection on biodiversity in the CCZ and recovery rates of impacted ecosystems; TMC’s ability to develop minerals in sufficient grade or quantities to justify commercial operations; the lack of development of seafloor polymetallic nodule deposit; uncertainty in the estimates for mineral resource calculations from certain contract areas and for the grade and quality of polymetallic nodule deposits; risks associated with natural hazards; uncertainty with respect to the specialized treatment and processing of polymetallic nodules that TMC may recover; risks associated with collective, development and processing operations; fluctuations in transportation costs; testing and manufacturing of equipment; risks associated with TMC’s limited operating history; the impact of the COVID-19 pandemic; risks associated with TMC’s intellectual property; and other risks and uncertainties, including those under Item 1A “Risk Factors” in TMC’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, filed by TMC with the Securities and Exchange Commission (“SEC”) on November 15, 2021, and in TMC’s other future filings with the SEC. TMC cautions that the foregoing list of factors is not exclusive. TMC cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. TMC does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based except as required by law.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/daa001c7-4980-4269-b505-016453f1695d

March 31, 2022

• Industry leading vendor-neutral solution for automated 2D and 3D quantification for browser-accessible echocardiography analysis and reporting
• New solution provides seamless diagnostic workflows and identical applications, on and off the ultrasound cart
• Artificial intelligence (AI) driven automated image analysis and quantification features help increase efficiency and diagnostic quality

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Ultrasound Workspace [OLK1] at the American College of Cardiology’s Annual Scientific Session & Expo (ACC 2022). Philips Ultrasound Workspace [1] is an industry leading vendor-neutral echocardiography image analysis and reporting solution that can be accessed remotely via a browser. Clinicians can now leverage seamless diagnostic workflows from the ultrasound exam room to the reporting room and beyond, wherever echocardiography data needs to be reviewed and analyzed.

By offering cardiologists a consistent set of on and off cart AI-driven image analysis and quantification tools, this next-generation echocardiography solution helps to improve productivity and consistency while also enhancing diagnostic quality. Access to archived legacy data, combined with off cart vendor neutral analysis capabilities, further enhances consistent quantification across all echo labs at all locations.

“With its new remote, browser-based accessibility, Philips Ultrasound Workspace is the first advanced vendor-neutral 2D/3D echocardiography viewing, analysis, and reporting system that extends the superior user experience of Philips’ cardiac ultrasound system EPIQ CVx into multiple connected environments,” said Jeff Cohen, General Manager of Ultrasound at Philips. “We have combined the power of AI with deep clinical knowledge to create a solution that integrates into the workflows of healthcare providers to help drive efficient clinical decision-making. With Ultrasound Workspace, our customers can experience a whole new world of echocardiography workflow to help improve both the patient and staff experience.”

Irrespective of location [2], with Ultrasound Workspace, the same user interface and AI-enabled image analysis and quantification tools are now accessible to help speed up quantitative measurements such as left ventricular ejection fraction, increase diagnostic confidence, and improve inter-observer and intra-observer consistency. In addition to extending the user experience of Philips’ Ultrasound System – EPIQ CVx – Ultrasound Workspace also features vendor-neutral application and data source capabilities.

“Philips has been instrumental in moving the field of 3D echocardiography forward. Their software, which is consistently developed with input from physicians, has been a true help for the echo community in general,” said Roberto M. Lang, MD, Director, Noninvasive Cardiac Imaging Laboratories at University of Chicago Medical Center, who has published multiple papers on the use of AI and machine learning in echocardiography.

Philips Ultrasound Workspace is a holistic, scalable, cardiovascular viewing, analysis and reporting system that enables greater efficiency by giving care teams the flexibility to adopt workflows based on their individual needs. Leveraging AI for speed and diagnostic confidence and capable of analyzing vendor-agnostic data, it offers an agile technology platform, flexible licensing for small- to large-scale organizations, and comprehensive application support. It also incorporates quality assessment capabilities on American Society of Echocardiography (ASE) and Intersocietal Accreditation Commission (IAC) standards. Ultrasound Workspace can be deployed either stand-alone or deeply integrated into PACS and EMR echocardiography reading workflows.

For more information on Philips Ultrasound Workspace and other new cardiology solutions designed to strengthen clinical confidence, build efficiency and help improve cardiac care experiences, visit Philips at ACC 2022 (April 2 – 4, Washington, DC) and follow @PhilipsLiveFrom for #ACC22 updates throughout the event.

[1] Ultrasound Workspace is the commercial name of TOMTEC-ARENA software developed by TOMTEC Imaging Systems GmbH – a company that Philips acquired in 2017. Ultrasound Workspace replaces Philips’ existing QLAB cardiovascular ultrasound quantification software. TOMTEC-ARENA is a trademark of TOMTEC Imaging Systems GmbH.
[2] Remote access requires a secure VPN connection.

For further information, please contact:

Kathy O’Reilly
Philips Global Press Office
Tel.: +1 978-221-8919
E-mail : kathy.oreilly@philips.com
Twitter: @kathyoreilly

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

• Clinicians reviewing ultrasound scan

Over half of consumers express frustration, shop elsewhere, when their responses to brand messages go unanswered

STOCKHOLM, Sweden, and ATLANTA — March 31, 2022 — Consumers are being unintentionally ignored by businesses, according to a new study of almost 3,000 consumers across 15 countries, commissioned by Sinch (Sinch AB (publ) – XSTO: SINCH). The study found 89% of people want to initiate and reply to two-way conversations with businesses, via multiple mobile and social channels. However, over half (53%) recalled a frustrating time when they discovered they could not reply to a mobile message sent from a business, for example to ask a question, receive an update or complete an action, such as scheduling an appointment. Download the full report here.

Delayed Responses Mean Dissatisfaction
Even brands that have deployed some two-way communication are struggling to meet consumers’ expectations, the report found. When asked how long it typically takes to get a response from a brand on social media, nearly one in four people claimed it takes a day or longer. Most respondents said they’d be less likely to buy from a brand given these unreasonable wait times. Scaling two-way messaging across mobile channels to deliver the immediacy customers expect requires greater attention and tools that can efficiently come via a top CPaaS platform.

AI in Team?
The study found 70% of people had interacted with an AI-powered chatbot at least once – but what happens when a live service agent needs to step in? A resounding 95% of respondents desired to be instantly handed off to a live agent in these situations — a stark contrast to the 35% of businesses currently enabling this, according to a recent IDC white paper.

The study amplifies the imbalance between consumers’ desire for more intimate digital brand interactions and the limitations of brands’ current one-way messaging realities.

“Our research shows that customers are ready to take their relationships with brands to the next level, with two-way messaging across channels that gives them the freedom to shape the conversation to their needs,” said Jonathan Bean, CMO of Sinch. “However, because many brands aren’t yet equipped to provide this enhanced conversational experience, customers are being unintentionally ignored, which can lead them to abandon a business altogether. Activating omnichannel two-way messaging is a critical way of boosting the customer experience and forging more loyal, satisfied relationships with consumers.”

The online study of 2,980 consumers across 15 countries was conducted by Ravn Research in October 2021. To read the full report, visit here.

About Sinch
Sinch’s leading cloud communications platform lets businesses reach everyone on the planet, in seconds or less, through mobile messaging, email, voice and video. More than 150,000 businesses, including many of the world’s largest companies and mobile operators, use Sinch’s advanced technology platform to engage with their customers. Sinch has been profitable and fast-growing since its foundation in 2008. It is headquartered in Stockholm, Sweden, and has a local presence in more than 50 countries. Shares are traded at NASDAQ Stockholm: XSTO:SINCH. Visit us at sinch.com.

For further information, please contact:

Jeff Hasen
Vice President, Communications
jeff.hasen@sinch.com

Attachment

• CX-report-2022–PR

Kither Biotech announces publication of new data in Science Translational Medicine

Data support the use of Kither Biotech’s lead asset, KIT2014, in obstructive airway diseases

KIT2014 demonstrated a triple mechanism of action in reversing disease pathogenesis: enhancing functionality of CFTR channels and reducing bronchoconstriction and inflammation

Adds to evidence supporting the use of KIT2014 as a potential add-on therapy to current cystic fibrosis standard of care

Turin, Italy, 31 2022 – Kither Biotech (“Kither” or “the Company”), a biopharmaceutical company developing novel therapies for rare respiratory diseases, today announces the publication of a study in Science Translational Medicine describing the mechanism of action of its lead asset, KIT2014, and proof-of-concept data for its use for the treatment of chronic obstructive airway diseases (Sci. Transl. Med., 14 (638), eabl6328. • DOI: 10.1126/scitranslmed.abl6328).

KIT2014 is a novel, cell-permeable peptide currently being investigated for the treatment of cystic fibrosis (CF) that works to modulate cyclic adenosine monophosphate (cAMP) levels inside cells. Increasing cAMP can reduce mucus accumulation, inflammation, and bronchoconstriction, issues that are inherent to cystic fibrosis. KIT2014 is currently being developed as an add-on to the current standard of care enabling improved efficacy by directly focusing on the most significant ailments of CF patients, delivered directly to the lungs as an inhaled therapy. The Company expects to begin a Phase 1/2A clinical trial of KIT2014 in 2023.

The data demonstrate the therapeutic potential of inhaled KIT2014 (referred to as PI3Kγ MP in the publication) to increase cAMP levels in pulmonary cells, alleviating the pathogenesis of several obstructive airway diseases, such as cystic fibrosis, asthma and COPD, through a triple mechanism of action: promoting bronchodilation, reducing lung inflammation, and enhancing the activity of the cystic fibrosis transmembrane conductance regulator (CFTR), the channel that triggers mucus hydration and clearance. In airway cells from patients with cystic fibrosis, a disease where CFTR dysfunction is particularly critical, KIT2014 was reported to enhance the effects of existing CFTR modulators by up to 80%.

Vincent Metzler, CEO at Kither Biotech, commented: “The publication of these data in a prominent peer-reviewed journal represents an important step as we advance the development of KIT2014 for the treatment of cystic fibrosis as an add-on therapy to CFTR modulators. We are preparing for our Phase 1/2A clinical trial of KIT2014, as we move one step closer to potentially bringing this innovative therapy to patients with unmet need.”

Alessandra Ghigo, scientific co-founder at Kither Biotech and lead investigator, said: “These new data validate KIT2014’s ability to modulate cAMP signal transduction in the lungs, increasing the functionality of CFTR channels, as well as reducing inflammation and bronchoconstriction, properties which are potentially highly beneficial to patients with cystic fibrosis and other diseases like COPD and asthma. We are looking forward to commencing clinical trials for KIT2014.”

Emilio Hirsch, scientific co-founder at Kither Biotech and last author, added: “Our data of KIT2014 showing an enhancement of the effect of existing CFTR modulators by 80% demonstrate the potential of this peptide, when administered as an inhalation therapy, to improve the condition of many patients still suffering from CF or other respiratory diseases.”

ENDS

About Kither Biotech
Kither Biotech is a biopharma company founded by Prof. Alessandra Ghigo, Prof. Emilio Hirsch, Prof. Alberto Bardelli and Marco Kevin Malisani. The company aims to identify and develop new drug candidates for the treatment of rare pulmonary diseases, with specific focus on cystic fibrosis and idiopathic pulmonary fibrosis. Kither Biotech is a spin-off from the University of Turin and actively collaborates with the Molecular Biotechnology Center (University of Turin) and other research centres in the world. The company developed a pipeline of treatments currently under preclinical development, with programs in cystic fibrosis, idiopathic pulmonary fibrosis and other respiratory diseases. |www.kitherbiotech.com

About KIT2014

KIT2014 is a cell-permeable cAMP modulating peptide that disrupts the interaction of PI3Kgamma with its partner, protein kinase A (PKA), leading to type 3 and 4 phosphodiesterases (PDE3/4) inhibition and, in turn, to enhanced cAMP responses within the cell. KIT2014 is currently being investigated for the treatment of cystic fibrosis (CF) as an add-on inhalation therapy to the current standard of care, enabling improved efficacy by directly impacting mucus hypersecretion, airway inflammation and bronchoconstriction, the most significant ailments of CF patients. When inhaled, KIT2014 increases cAMP locally in bronchial epithelial cells to promote the opening of CFTR chloride channels, which are key to mucus hydration, while in lung smooth muscle and immune cells cAMP elevation limits bronchoconstriction and neutrophil infiltration. In CF patients, treatment with KIT2014 is believed to restore the function of CFTR mutants by potentiating the effects of CFTR modulators (Ghigo et al., Science Translational Medicine, in press).

For more information please contact:

Consilium Srategic Communications Matthew Cole / Davide Salvi / Lucie Foster KitherBiotech@consilium-comms.com

Tel: +44 (0) 20 3709 5700

Click HERE for the Italian version of the release